Safety Optimization: Managing Off-Target Toxicities in ADCs
Despite their targeted mechanism of action, ADCs can still cause significant off-target toxicities due to premature drug release or non-specific binding. Managing these risks is critical to the success of the ADC market and patient outcomes.
Off-target effects often stem from linker instability, resulting in the release of cytotoxic drugs into the systemic circulation. This can lead to damage in healthy tissues, particularly the liver, kidneys, and bone marrow. Additionally, non-specific uptake by Fc receptors or other unintended cellular mechanisms may contribute to adverse events.
To mitigate these risks, developers are focusing on optimizing linkers to be more stable in circulation and cleavable only under specific intracellular conditions (e.g., low pH or enzymatic activity). Hydrophilic linkers are also being used to reduce non-specific interactions and improve the pharmacokinetic profile.
Another approach involves the use of less toxic payloads or modifying the payload structure to enhance selectivity. ADCs with moderate potency but improved safety margins are gaining interest, especially for chronic administration.
Patient selection and dosing strategies play an equally important role. Biomarker-based selection ensures that ADCs are administered to individuals most likely to respond with minimal toxicity. Meanwhile, dose fractionation and extended dosing intervals help reduce systemic toxicity.
Ongoing research in predictive toxicology, in vitro modeling, and animal testing will further support safety optimization in ADC development.